Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature.
BACKGROUND
Tumour necrosis factor antagonists (anti-TNF-α) have demonstrated the efficacy in different chronic immune inflammatory disorders. Within the spectrum of adverse events, autoimmune diseases have been observed, including cases of alopecia areata (AA).


OBJECTIVE
The objective of the study is to characterize AA developed during anti-TNF-α therapy.


METHODS
We present five new cases and review all the cases reported in the literature (eleven).


RESULTS
One third of the cases had a positive (personal or family) history of AA. Most of them presented with rapid extensive AA, usually involving the ophiasis area. Prognosis was usually poor, with slight response to treatments. In the cases where anti-TNF-α therapy was maintained, the course did not seem to change.


CONCLUSIONS
Although rare, AA developed during anti-TNF-α therapy might be more frequent than suggested by reports of isolated cases. Personal and family history of autoimmune disease might alert clinicians to their possible development or relapse once the anti-TNF-α therapy is started.
Ferran
M
M
Departments of Dermatology Rheumatology, Hospital del Mar, IMAS, Barcelona, Spain. mferran@hospitaldelmar.cat
Calvet
J
J
Almirall
M
M
Pujol
R M
RM
Maymó
J
J
D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha